In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2

Cytokine

Volumn 16, Issue 6, 2001, Pages 239-250

  Neville, Mary E ^a   Robb, Richard J ^a   Popescu, Mircea C ^a  

^a Biomira USA Inc   (United States)

Author keywords

Cancer vaccine; Cytokines; In situ vaccine; Liposome; Melanoma

Indexed keywords

CD3 ANTIGEN; INTERLEUKIN 2; LIPOSOME; TUMOR ANTIGEN; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER SURGERY; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; GENETIC PROCEDURES; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INFLAMMATORY CELL; LYMPHOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

ANIMALIA;

EID: 0035931043     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2001.0963     Document Type: Article

References (29)

1. Towards development of T-cell vaccines
2. Cancer vaccines
3. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
4. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trail
5. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma
6. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
7. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma vaccine preceded by cyclophosphamide
8. Preparation and characterization of a polyvalent human antigen vaccine
9. The onset and extent of genomic instability in sporadic colorectal tumor progression
10. Anti-tumor vaccine adjuvant effects of IL-2 liposomes in mice immunized against MCA-102 sarcoma
11. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposomes-encapsulated IL-2 as depot formulation
12. Regression of bladder tumors on mice treated with interleukin-2 gene modified tumor cells
13. Vacination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific, long-lasting anti-tumor immunity
14. Strong cytotoxic lymphocytes response to a macrophage inflammatory protein let-expressing tumor: Linkage between inflammation and specific immunity
15. Tumor inhibition by interleukin 2 at the tumor/host interface
16. The design of a pharmaceutically acceptable liposomal formulation of recombinant interleukin 2 (rIL-2) for locoregional anticancer immunotherapy
17. Effect of local interleukin-2 on spontaneous tumors of different immunogenic strength
18. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity
19. Combination of interleukin 12 and interferon α gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma
20. Biopharmaceutics of liposomal IL-2, Oncolipin
21. Interleukin-2 induced SUV coalescence
22. In vivo cytotoxic responses induced by allogenic and neoplastic cells in mice: Relative lack of immunogenicity of B16 melanoma cells
23. Anti-tumor effects of interleukin 1β: In vivo induction of immunity to B16 melanoma, a non-immunogenic tumor
24. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody; abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo
25. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1β II. Mechanism of inhibition: The role of polymorphonuclear leukocytes
26. Transforming growth factor production by chemically transformed cells
27. Transforming growth factor type-β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
28. T cell growth factor: Parameters of production and a quantitative microassay for activity
29. 3H]thymidine incorporation assay